NSC697923

Catalog No.S7142 Batch:S714201

Print

Technical Data

Formula

C11H9NO5S
Molecular Weight 267.26 CAS No. 343351-67-7
Solubility (25°C)* In vitro DMSO 53 mg/mL (198.3 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO Corn oil

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 2.650mg/ml (9.92mM) Taking the 1 mL working solution as an example, add 50 μL of 53 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description NSC697923 is a cell-permeable and selective inhibitor of the Ub-conjugating enzyme (E2) complex Ubc13-Uev1A.
Targets
E2 complex Ubc13-Uev1A [1]
In vitro NSC697923 selectively inhibits PMA-induced NF-κB activation, and also inhibits IκBα phosphorylation by both RANKL and LPS. This compound impedes the formation of the Ubc13 and ubiquitin thioester conjugate and suppresses constitutive NF-κB activity in ABC-DLBCL cells. In addition, it inhibits the proliferation and survival of ABC-DLBCL cells and GCB-DLBCL cells, and also induces apoptosis of primary DLBCL cells. In neuroblastoma (NB) cell lines, this chemical shows cytotoxic effect, and inhibits both anchorage-dependent and -independent colony formation.
In vivo NSC697923 (5 mg/kg/day, i.p.) demonstrates potent antitumor efficacy in both NB SH-SY5Y and NGP xenografts.

Protocol (from reference)

Kinase Assay:[1]
  • In vitro ubiquitination assay

    The reactions are carried out at 37°C for 40 minutes in a buffer containing 50mM Tris-HCl, pH 7.5, 5mM MgCl2, 200μM ATP, 120μM Ub (U-100H), and 0.1μM E1 (E-304). For Ubc13-mediated Ub chain synthesis, the reaction mixture includes 0.2 μM Ubc13 (E2-600) and 0.2 mM Uev1A (E2-662) with or without GST-TRAF6. For UbcH5c-catalyzed ubiquitination, UbcH5c (E2-627) instead of Ubc13 and Uev1A is used in the reaction. Compound NSC697923 is added into the reaction mixtures at the indicated concentrations. The reactions are terminated with an equal volume of SDS-PAGE sample buffer and the products are analyzed by Western blotting with a Ub-specific antibody. For detecting the E2-Ub (Ubc13∼Ub or UbcH5c∼Ub) thioester conjugates, the reactions are carried out as described in “In vitro ubiquitination assay” without GST-TRAF6. The reactions are terminated by the addition of the SDS-PAGE sample buffer without a reducing agent unless specified. The products are analyzed by Western blotting with an anti-Ubc13 or anti-UbcH5c antibody.
Cell Assay:[1]
  • Cell lines

    BC-DLBCL, GCB-DLBCL and primary DLBCL cells.

  • Concentrations

    ~1 μM

  • Incubation Time

    24 hours

  • Method

    Cell viability is measured by trypan blue exclusion assay following the manufacturer's instructions.
Animal Study:[2]
  • Animal Models

    SH-SY5Y and NGP xenografts.

  • Dosages

    ~5 mg/kg/day

  • Administration

    i.p.

References

  • https://pubmed.ncbi.nlm.nih.gov/22791293/
  • https://pubmed.ncbi.nlm.nih.gov/24556694/

Customer Product Validation

Immunofluorescence analysis of b-actin distribution and Lys63 ubiquitination in HK2 cells. Cells were preincubated with the specific inhibitor of the Ubc13–Uev1A complex NSC697923, in the indicated conditions before D-glucose was added. The results represent 4 independent experiments.

Data from [ , , FASEB J, 2017, 31(1):308-319 ]

Effect of lys63 ubiquitination inhibition on HG-induced LC3 and p62 protein expression in HK2 cells. Cells were pre-incubated with the inhibitor NSC697923, in the specific conditions before adding Dglucose. a, d Immunofluorescence analysis of LC3 and p62 puncta and lysine63 ubiquitinated proteins after 48 h of HG stimulation.

Data from [ , , J Mol Med (Berl), 2018, 96(7):645-659 ]

Selleck's NSC697923 Has Been Cited by 25 Publications

Evaluating biological activity of compounds by transcription factor activity profiling [ Science Advances, September 26, 2018, eaar4666] PubMed: 30263952
Ubiquitination status does not affect Vps34 degradation [ Genes & Diseases, September 2020, 401-407] PubMed: 37503842
CRISPR-Cas9 knockout screen identifies novel treatment targets in childhood high-grade glioma [ Clinical Epigenetics, May 9, 2023, 80] PubMed: 37161535
Ube2v1-mediated ubiquitination and degradation of Sirt1 promotes metastasis of colorectal cancer by epigenetically suppressing autophagy [ Journal of Hematology & Oncology, July 17, 2018, 95] PubMed: 30016968
Covalent inhibition of Plasmodium falciparum Ubc13 impairs global protein synthesis [ iScience, April 28, 2025, 112545] PubMed: 40491475
TLR4 endocytosis and endosomal TLR4 signaling are distinct and independent outcomes of TLR4 activation [ EMBO Rep, 2025, 10.1038/s44319-025-00444-2] PubMed: 40204912
TLR4 endocytosis and endosomal TLR4 signaling are distinct and independent outcomes of TLR4 activation [ EMBO Reports, 2025, 2740–2766] PubMed: 40204912
Covalent inhibition of Plasmodium falciparum Ubc13 impairs global protein synthesis [ iScience, 2025, 112545] PubMed: 40491475
Polyubiquitinated PCNA triggers SLX4-mediated break-induced replication in alternative lengthening of telomeres (ALT) cancer cells [ Nucleic Acids Research, 2024, gkae785] PubMed: 39291733
Polyubiquitinated PCNA triggers SLX4-mediated break-induced replication in alternative lengthening of telomeres (ALT) cancer cells [ Nucleic Acids Res, 2024, gkae785] PubMed: 39291733

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.